Skip to main content
SpringerLink
Log in

Acute Graft-versus-Host Disease

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J.Natl.Cancer Inst. 1951; 12:197–201.

    PubMed  CAS  Google Scholar 

  2. Elkins WL. Cellular immunology and the pathogenesis of graft versus host reactions (Review). Prog.Allergy 1971; 15:78–187.

    PubMed  CAS  Google Scholar 

  3. van Bekkum DW, de Vries MJ. Radiation chimaeras. London: Logos Press Limited, 1967.

    Google Scholar 

  4. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York: Academic Press, 1966:21–78.

    Google Scholar 

  5. Mathé G, Jammet H, Pendic B, Schwarzenberg L, Duplan J-F, Maupin B et al. Transfusions et greffes de moelle osseuse homologue chez des humains irradiés a haute dose accidentellement. Rev.Franc.Etudes Clin.et Biol. 1959; IV:226–238.

    Google Scholar 

  6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18:295–304.

    PubMed  CAS  Google Scholar 

  7. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756–762.

    PubMed  CAS  Google Scholar 

  8. Mielcarek M, Burroughs L, Leisenring W, Diaconescu R, Martin PJ, Sandmaier BM et al. Prognostic relevance of “early-onset” graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br.J.Haematol. 2005; 129:381–391.

    PubMed  Google Scholar 

  9. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005; 11:945–956.

    PubMed  Google Scholar 

  10. Hess AD, Jones RJ. Autologous graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation, 2nd Edition. Boston: Blackwell Science, 1999:342–348.

    Google Scholar 

  11. Graft-vs.-Host Disease. New York, NY: Marcel Dekker, 2005.

    Google Scholar 

  12. Sviland L, Dickinson AM. A human skin explant model for predicting graft-versus-host disease following bone marrow transplantation. J.Clin.Pathol. 1999; 52:910–913.

    PubMed  CAS  Google Scholar 

  13. Vogelsang GB, Hess AD, Berkman AW, Tutschka PJ, Farmer ER, Converse PJ et al. An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants. N.Engl.J.Med. 1985; 313:645–650.

    PubMed  CAS  Google Scholar 

  14. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T cell precursors as predictors of acute graft-versus-host diseasein bone marrow transplantation between HLA-identical siblings. N.Engl.J.Med. 1992; 327:1613–1617.

    PubMed  CAS  Google Scholar 

  15. Dickinson AM, Sviland L, Wang XN, Jackson G, Taylor PR, Dunn A et al. Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Transplantation 1998; 66:857–863.

    PubMed  CAS  Google Scholar 

  16. Wang XN, Taylor PR, Skinner R, Jackson GH, Proctor SJ, Hedley D et al. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Transplantation 2000; 70:488–493.

    PubMed  CAS  Google Scholar 

  17. Nichols WC, Antin JH, Lunetta KL, Terry VH, Hertel CE, Wheatley MA et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood 1996; 88:4429–4434.

    PubMed  CAS  Google Scholar 

  18. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva WAJ, Latouche A et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100:3908–3918.

    PubMed  CAS  Google Scholar 

  19. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br.J.Haematol. 2001; 113:807–813.

    PubMed  CAS  Google Scholar 

  20. Takahashi H, Furukawa T, Hashimoto S, Suzuki N, Kuroha T, Yamazaki F et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000; 26:1317–1323.

    PubMed  CAS  Google Scholar 

  21. Lin M-T, Storer B, Martin PJ, Tseng L-H, Grogan B, Chen P-J et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor β genotype of donor. Blood 2005; 106:3995–4001.

    PubMed  CAS  Google Scholar 

  22. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N.Engl.J.Med. 2001; 345:1794–1800.

    PubMed  CAS  Google Scholar 

  23. Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program experience. Blood 2001; 98:2922–2929.

    PubMed  CAS  Google Scholar 

  24. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat.Med. 2002; 8:410–414.

    PubMed  CAS  Google Scholar 

  25. Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompat-ibility antigens after bone marrow transplantation. Transplantation 1998; 66:910–916.

    PubMed  CAS  Google Scholar 

  26. Goulmy E, Schipper J, Pool J, Blokland E, Falkenburg JHF, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N.Engl.J.Med. 1996; 334:281–285.

    PubMed  CAS  Google Scholar 

  27. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98:2043–2051.

    PubMed  CAS  Google Scholar 

  28. Tseng L-H, Lin M-T, Hansen JA, Gooley T, Pei J, Smith AG et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999; 94:2911–2914.

    PubMed  CAS  Google Scholar 

  29. Korngold R. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant. 1992; 9:355–364.

    PubMed  CAS  Google Scholar 

  30. Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW et al. A phase I–II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94:2192–2199.

    PubMed  CAS  Google Scholar 

  31. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57:82–87.

    PubMed  CAS  Google Scholar 

  32. Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant. 1999; 23:443–450.

    PubMed  CAS  Google Scholar 

  33. Kernan NA. T-cell depletion for the prevention of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation, 2nd Edition. Boston: Blackwell Science, 1999:186–196.

    Google Scholar 

  34. Soiffer RJ, Martin P. T-cell depletion of allogeneic hematopoietic stem cell grafts. In: Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner MK, editors. Clinical Bone Marrow and Blood Stem Cell Transplantation. Third ed. Cambridge, UK: Cambridge University Press, 2004:416–425.

    Google Scholar 

  35. Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1997; 19:1001–1009.

    PubMed  CAS  Google Scholar 

  36. Pei J, Farrell C, Hansen JA, Juji T, Keever-Taylor CA, Knowles S et al. Evaluation of the limiting dilution cytotoxic T lymphocyte precursor frequency (fCTLp) assay in a multicenter study. In: Charron D, editor. HLA Genetic Diversity of HLA Functional and Medical Implication, Volume II. Paris, France: EDK, 1997:577–579.

    Google Scholar 

  37. Kircher B, Niederwieser D, Gachter A, Latzer K, Eibl G, Gastl G et al. No predictive value of cytotoxic or helper T-cell precursor frequencies for outcome when analyzed from the graft after stem cell transplantation. Ann.Hematol. 2004; 83:566–572.

    PubMed  Google Scholar 

  38. Healey G, Schwarer AP. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilized peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002; 30:341–346.

    PubMed  CAS  Google Scholar 

  39. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hemat-opoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254–2262.

    PubMed  CAS  Google Scholar 

  40. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51:1197–1203.

    PubMed  CAS  Google Scholar 

  41. Stern M, Passweg JR, Locasciulli A, Socie G, Schrezenmeier H, Bekassy AN et al. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation 2006; 82:218–226.

    PubMed  Google Scholar 

  42. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant. 1995; 16:747–753.

    PubMed  CAS  Google Scholar 

  43. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disese after allogeneic blood stem cell transplantation. Blood 1999; 94:1465–1470.

    PubMed  CAS  Google Scholar 

  44. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80:1838–1845.

    PubMed  CAS  Google Scholar 

  45. Bross DS, Tutschka PJ, Farmer ER, Beschorner WE, Braine HG, Mellits ED et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63:1265–1270.

    PubMed  CAS  Google Scholar 

  46. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E et al. Risk factors for acute graft-versus-host disease. Br.J.Haematol. 1987; 67:397–406.

    PubMed  CAS  Google Scholar 

  47. Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003; 75:2135–2143.

    PubMed  CAS  Google Scholar 

  48. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol.Blood.Marrow. Transplant. 2004; 10:178–185.

    Google Scholar 

  49. Storb R, Prentice RL, Hansen JA, Thomas ED. Association between HLA-B antigens and acute graft-versus-host disease. Lancet 1983; 2:816–819.

    PubMed  CAS  Google Scholar 

  50. Baughan AS, Worsley AM, McCarthy DM, Hows JM, Catovsky D, Gordon-Smith EC et al. Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy. Br.J.Haematol. 1984; 56:445–454.

    PubMed  CAS  Google Scholar 

  51. Gratama JW, Sinnige LGF, Zwaan FE, van Heugten JG, Onjnen T, The TH et al. Marrow donor immunity to herpes simplex virus: association with acute graft-versus-host disease. Exp.Hematol. 1987; 15:735–740.

    PubMed  CAS  Google Scholar 

  52. Seebach JD, Stussi G, Passweg JR, Loberiza FR, Jr., Gajewski JL, Keating A et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11:1006–1013.

    PubMed  Google Scholar 

  53. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001; 27:777–783.

    PubMed  CAS  Google Scholar 

  54. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7:39–44.

    PubMed  CAS  Google Scholar 

  55. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. Lancet 2005; 366:733–741.

    PubMed  CAS  Google Scholar 

  56. Martin P, Nash R, Sanders J, Leisenring W, Anasetti C, Deeg HJ et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1998; 21:273–279.

    PubMed  CAS  Google Scholar 

  57. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96:2062–2068.

    PubMed  CAS  Google Scholar 

  58. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br.J.Haematol. 1997; 97:855–864.

    PubMed  CAS  Google Scholar 

  59. Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation (concise report). Blood 1986; 67:1172– 1175.

    PubMed  CAS  Google Scholar 

  60. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78:2139–2149.

    PubMed  CAS  Google Scholar 

  61. Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995; 16:175–182.

    PubMed  CAS  Google Scholar 

  62. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964–2968.

    PubMed  CAS  Google Scholar 

  63. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation (Review). Bone Marrow Transplant. 2001; 27:893–898.

    PubMed  CAS  Google Scholar 

  64. Crider MK, Jansen J, Norins AL, McHale MS. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch.Dermatol. 1986; 122:1023–1027.

    PubMed  CAS  Google Scholar 

  65. Ruiz-Genao DP, GF-Villalta MJ, Penas PF, Fraga J, Garcia-Diez A, Fernandez-Herrera J. Pustular acral erythema in a patient with acute graft-versus-host disease. Journal of the European Academy of Dermatology & Venereology 2003; 17:550– 553.

    CAS  Google Scholar 

  66. Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100:3903–3907.

    PubMed  CAS  Google Scholar 

  67. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59:1015–1022.

    PubMed  CAS  Google Scholar 

  68. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant. 1993; 11:21–26.

    PubMed  CAS  Google Scholar 

  69. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B et al. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 1990; 76:624–629.

    PubMed  CAS  Google Scholar 

  70. Kraus MD, Feran-Doza M, Garcia-Moliner ML, Antin J, Odze RD. Cytomegalovirus infection in the colon of bone marrow transplantation patients. Mod.Pathol. 1998; 11:29–36.

    PubMed  CAS  Google Scholar 

  71. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' Hematopoietic Cell Transplantation. Third ed. Oxford, UK: Blackwell Publishing Ltd., 2004:286–299.

    Google Scholar 

  72. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10:320–327.

    PubMed  Google Scholar 

  73. Spencer GD, Hackman RC, McDonald GB, Amos DE, Cunningham BA, Meyers JD et al. A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 1986; 42:602–607.

    PubMed  CAS  Google Scholar 

  74. Wu D, Hockenbery DM, Brentnall TA, Baehr PH, Ponec RJ, Kuver R et al. Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. Transplantation 1998; 66:1319–1324.

    PubMed  CAS  Google Scholar 

  75. McDonald GB, Cruickshank S, Rodell TC, Hockenberry DM. Oral beclamethasone dipropionate (BDP) for gastrointestinal GVHD: a corticosteroid-sparing treatment with improved survival at day +200. Biol Blood Marrow Transplant 2006; 12 (Suppl. 1):1–2. Abstract.

    Google Scholar 

  76. Klein SA, Martin H, Schreiber-Dietrich D, Hermann S, Caspary WF, Hoelzer D et al. A new approach to evaluating intestinal acute graft-versus-host disease by transabdominal sonography and colour Doppler imaging. Br.J.Haematol. 2001; 115:929–934.

    PubMed  CAS  Google Scholar 

  77. Mentzel HJ, Kentouche K, Kosmehl H, Gruhn B, Vogt S, Sauerbrey A et al. US and MRI of gastrointestinal graft-versus-host disease. Pediatr.Radiol. 2002; 32:195–198.

    PubMed  Google Scholar 

  78. Watkins TR, Chien JW, Crawford SW. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Seminars in Respiratory and Critical Care Medicine 2005; 26:482–489.

    PubMed  Google Scholar 

  79. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation (Review). Biol Blood Marrow Transplant 2001; 7:223–229.

    PubMed  CAS  Google Scholar 

  80. Yanik G, Cooke KR. The lung as a target organ of graft-versus-host disease (Review). Semin.Hematol. 2006; 43:42–52.

    PubMed  Google Scholar 

  81. Greenspan A, Deeg HJ, Cottler-Fox M, Sirdofski M, Spitzer TR, Kattah J. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease. Bone Marrow Transplant. 1990; 5:349–352.

    PubMed  CAS  Google Scholar 

  82. Padovan CS, Bise K, Hahn J, Sostak P, Holler E, Kolb HJ et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke 1999; 30:1651–1656.

    PubMed  CAS  Google Scholar 

  83. Takatsuka H, Okamoto T, Yamada S, Fujimori Y, Tamura S, Wada H et al. New imaging findings in a patient with central nervous system dysfunction after bone marrow transplantation. Acta Haematol. 2000; 103:203–205.

    PubMed  CAS  Google Scholar 

  84. Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am.J.Surg.Pathol. 1997; 21:988–996.

    PubMed  CAS  Google Scholar 

  85. Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch.Dermatol. 2000; 136:717–721.

    PubMed  CAS  Google Scholar 

  86. Massi D, Franchi A, Pimpinelli N, Laszlo D, Bosi A, Santucci M. A reappraisal of the histopathologic criteria for the diagnosis of cutaneous allogeneic acute graft-vs-host disease. Am.J.Clin.Pathol. 1999; 112:791–800.

    PubMed  CAS  Google Scholar 

  87. Sviland L, Pearson AD, Eastham EJ, Hamilton PJ, Proctor SJ, Malcolm AJ. Histological features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J.Clin.Pathol. 1988; 41:148–154.

    PubMed  CAS  Google Scholar 

  88. Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4:123–130.

    PubMed  CAS  Google Scholar 

  89. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988; 8:463–470.

    PubMed  CAS  Google Scholar 

  90. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995; 15:825–828.

    PubMed  CAS  Google Scholar 

  91. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106:1495–1500.

    PubMed  CAS  Google Scholar 

  92. Vogelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: Clinical characteristics in the cyclosporine era. Medicine 1988; 67:163–174.

    PubMed  CAS  Google Scholar 

  93. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after alloge-neic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:674–682.

    PubMed  Google Scholar 

  94. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM et al. An acute graft-versus-host disease activity index to predict survival after hemat-opoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108:749–755.

    PubMed  CAS  Google Scholar 

  95. Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WI, McDonald GB. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am.J.Surg.Pathol. 2000; 24:1004–1008.

    PubMed  CAS  Google Scholar 

  96. Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenberry DM, Flowers MED et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12:226–234.

    PubMed  Google Scholar 

  97. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89:2203–2209.

    PubMed  CAS  Google Scholar 

  98. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J.Exp.Med. 1985; 161: 718–730.

    PubMed  CAS  Google Scholar 

  99. Nelson JL. Microchimerism: incidental byproduct of pregnancy or active participant in human health? Trends in Molecular Medicine 2002; 8:109–113.

    PubMed  CAS  Google Scholar 

  100. Adams KM, Holmberg LA, Leisenring W, Fefer A, Guthrie KA, Tylee TS et al. Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation. Blood 2004; 104:1894–1897.

    PubMed  CAS  Google Scholar 

  101. Higgins MJ, Blackall DP. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion (Review). Current Hematology Reports 2005; 4:470–476.

    PubMed  Google Scholar 

  102. Juji T, Takahashi K, Shibata Y, Ide H, Sakakibara T, Ino T et al. Post-transfusion graft-versus-host disease in immuno-competent patients after cardiac surgery in Japan (Letter to Editor). N.Engl.J.Med. 1989; 321:56

    PubMed  CAS  Google Scholar 

  103. Greenbaum BH. Transfusion-associated graft-versus-host disease: Historical perspectives, incidence, and current use of irradiated blood products. J.Clin.Oncol. 1991; 9:1889–1902.

    PubMed  CAS  Google Scholar 

  104. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535–3542.

    PubMed  CAS  Google Scholar 

  105. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N.Engl.J.Med. 2004; 351:2265–2275.

    PubMed  CAS  Google Scholar 

  106. Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp.Hematol. 2004; 32:397–407.

    PubMed  CAS  Google Scholar 

  107. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N.Engl.J.Med. 1983; 308:302–307.

    PubMed  CAS  Google Scholar 

  108. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation (Review). J.Med. 1992; 23:161–173.

    PubMed  CAS  Google Scholar 

  109. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93:3267–3275.

    PubMed  CAS  Google Scholar 

  110. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED et al. Prolonged fluconazole prophylaxis is associated with persistent protection against cadidiasis-related death and gut GVHD in allogeneic marrow transplant recipients: long-term follow-up of a placebo controlled trial. Blood 1999; 94 (Suppl. 1):394a, #1748. Abstract.

    Google Scholar 

  111. Guthery SL, Heubi JE, Filipovich A. Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: results of a pilot study [erratum appears in Bone Marrow Transplant. 2005 Aug;36(4):371]. Bone Marrow Transplant. 2004; 33:1235–1239.

    PubMed  CAS  Google Scholar 

  112. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leuke-mia activity after experimental bone marrow transplantation. J.Clin.Invest. 2001; 107:1581–1589.

    PubMed  CAS  Google Scholar 

  113. Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 29:373–377.

    PubMed  CAS  Google Scholar 

  114. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in alloge-neic bone marrow transplantation. Blood 2002; 100:3479–3482.

    PubMed  CAS  Google Scholar 

  115. Vossen JM. Gnotobiotic measures for the prevention of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-Vs-Host Disease: Immunology, Pathophysiology, and Treatment. New York: Marcel Dekker, Inc., 1990:403–414.

    Google Scholar 

  116. Sala-Torra O, Martin PJ, Storer B, Sorror M, Storb RF, Sandmaier BM et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and non-myeloablative conditioining regimens. Blood 2006; 108 (Part 1):227a, #755. Abstract.

    Google Scholar 

  117. Uphoff DE. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc.Soc.Exp.Biol.Med. 1958; 99:651–653.

    PubMed  CAS  Google Scholar 

  118. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation. N.Engl.J.Med. 1975; 292:832–843, 895–902.

    PubMed  CAS  Google Scholar 

  119. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hema-tologic neoplasms. N.Engl.J.Med. 1989; 320:828–834.

    PubMed  CAS  Google Scholar 

  120. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1:327–329.

    PubMed  CAS  Google Scholar 

  121. Fay JW, Wingard JR, Antin JH, Collins RH, Piñeiro LA, Blazar BR et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87:3514–3519.

    PubMed  CAS  Google Scholar 

  122. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Japanese FK506 BMT Study Group. Bone Marrow Transplant. 2001; 28:181–185.

    PubMed  CAS  Google Scholar 

  123. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982; 34:30–35.

    PubMed  CAS  Google Scholar 

  124. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9:512–518.

    PubMed  Google Scholar 

  125. Horowitz MM, Przepiorka D, Bartels P, Buell DN, Zhang M-J, Fitzsimmons WE et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 1999; 5:180–186.

    PubMed  CAS  Google Scholar 

  126. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allo-geneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11:495–505.

    PubMed  CAS  Google Scholar 

  127. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course meth-otrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 34:621–625.

    PubMed  CAS  Google Scholar 

  128. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108:1485–1491.

    PubMed  CAS  Google Scholar 

  129. Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplant. 2004; 34:425–431.

    PubMed  CAS  Google Scholar 

  130. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999; 24:763–768.

    PubMed  CAS  Google Scholar 

  131. Bensinger W. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematologi-cal malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant. 2006; 38:539–546.

    PubMed  CAS  Google Scholar 

  132. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:328–336.

    PubMed  CAS  Google Scholar 

  133. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tac-rolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102:1601–1605.

    PubMed  CAS  Google Scholar 

  134. Ramsay NKC, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft-versus-host disease. N.Engl. J.Med. 1982; 306:392–397.

    PubMed  CAS  Google Scholar 

  135. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol.Blood.Marrow.Transplant. 2002; 8:468–476.

    PubMed  CAS  Google Scholar 

  136. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi G, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12:560–565.

    PubMed  Google Scholar 

  137. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78:122–127.

    PubMed  CAS  Google Scholar 

  138. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12:573–584.139. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allo-geneic stem-cell transplantation from unrelated donors using combined graft-ver-sus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J.Clin. Oncol. 2003; 21:506–513.

    PubMed  CAS  Google Scholar 

  139. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allo-geneic stem-cell transplantation from unrelated donors using combined graft-ver-sus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J.Clin. Oncol. 2003; 21:506–513.

    PubMed  Google Scholar 

  140. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis intransplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98:2942–2947.

    PubMed  CAS  Google Scholar 

  141. Lowsky R, Stockerl-Goldstein K, Laport G, Miklos D, Arai S, Shizuru J et al. Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using non-myeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity. Blood 2006; 108 (Part 1):182a, #603. Abstract.

    Google Scholar 

  142. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:117–130.

    PubMed  Google Scholar 

  143. Chakrabarti S, Hale G, Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplant.Proc. 2004; 36:1225–1227.

    PubMed  CAS  Google Scholar 

  144. Blaise D, Olive D, Hirn M, Viens P, Lafage M, Attal M et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant. 1991; 8:105–111.

    PubMed  CAS  Google Scholar 

  145. Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant. 1993; 12:531–536.

    PubMed  CAS  Google Scholar 

  146. Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004; 10: 552–560.

    PubMed  CAS  Google Scholar 

  147. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F et al. T-cell-depleted allogeneic bone marrow transplantation as pos-tremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91:1083–1090.

    PubMed  CAS  Google Scholar 

  148. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N.Engl. J.Med. 1999; 340:1704–1714.

    PubMed  CAS  Google Scholar 

  149. Cornelissen JJ, van der HB, Petersen EJ, Vindelov L, Russel CA, Hoglund M et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp.Hematol. 2003; 31:855–864.

    PubMed  CAS  Google Scholar 

  150. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95:2484–2490.

    PubMed  CAS  Google Scholar 

  151. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183–1186.

    PubMed  CAS  Google Scholar 

  152. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100:1977–1983.

    PubMed  CAS  Google Scholar 

  153. MacMillan ML, Weisdorf DJ, Davies SM, Defor TE, Burns LJ, Ramsay NK et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol.Blood.Marrow.Transplant. 2002; 8:40–46.

    PubMed  CAS  Google Scholar 

  154. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76:1464–1472.

    PubMed  CAS  Google Scholar 

  155. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991; 77:1821–1828.

    PubMed  CAS  Google Scholar 

  156. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-meth-ylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92:2288–2293.

    PubMed  Google Scholar 

  157. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107:4177–4181.

    PubMed  Google Scholar 

  158. McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115:28–35.

    PubMed  CAS  Google Scholar 

  159. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant. 1999; 24:1185–1189.

    PubMed  CAS  Google Scholar 

  160. Ohashi Y, Minegishi M, Fujie H, Tsuchiya S, Konno T. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. Bone Marrow Transplant. 1997; 19:625–627.

    PubMed  CAS  Google Scholar 

  161. Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant. 2000; 26:985–991.

    PubMed  CAS  Google Scholar 

  162. Graziani F, V. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica 2002; 87:973–978.

    PubMed  CAS  Google Scholar 

  163. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithy-mocyte globulin (ATG). Bone Marrow Transplant. 2001; 28:1093–1096.

    PubMed  CAS  Google Scholar 

  164. Khoury H, Kashyap A, Brewster C, Gilfillan KR, Adkins D, Brown R et al. Anti-thymocyte globulin (ATG) for steroid-resistant acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a costly therapy with limited benefits. Blood 1999; 94 (Suppl. 1):668a, #2962. Abstract.

    Google Scholar 

  165. Mollee P, Morton AJ, Irving I, Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-ver-sus-host disease developing during cyclosporine prophylaxis. [erratum appears in Br J Haematol 2001 Oct;115(1):235.]. Br.J.Haematol. 2001; 113:217–223.

    PubMed  CAS  Google Scholar 

  166. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72:1924–1929.

    PubMed  CAS  Google Scholar 

  167. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998; 22:61–65.

    PubMed  CAS  Google Scholar 

  168. van Oosterhout YV, van Emst L, Schattenberg AV, Tax WJ, Ruiter DJ, Spits H et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 2000; 95:3693–3701.

    PubMed  Google Scholar 

  169. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88:824–830.

    PubMed  CAS  Google Scholar 

  170. Cragg L, Blazar BR, DeFor T, Kolatker N, Miller W, Kersey J et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol. Blood.Marrow.Transplant. 2000; 6:441–447.

    PubMed  CAS  Google Scholar 

  171. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploiden-tical mesenchymal stem cells. Lancet 2004; 363:1439–1441.

    PubMed  Google Scholar 

  172. Kebriaei P, Isola L, Bahceci E, Holland HK, Rowley S, McGuirk J et al. Phase II trial of Prochymal™ (ex-vivo cultured adult human mesenchymal stem cells) andcorticosteroids as primary treatment for acute graft-vs-host disease (aGVHD). Blood 2006; 108 (Part 1):922a, #3231. Abstract.

    Google Scholar 

  173. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur.J.Haematol. 2004; 73:56–61.

    PubMed  CAS  Google Scholar 

  174. Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant. 1995; 15:891–894.

    PubMed  CAS  Google Scholar 

  175. Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92:4066–4071.

    PubMed  CAS  Google Scholar 

  176. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABX-CBL. Blood 2001; 98:2052–2058.

    PubMed  CAS  Google Scholar 

  177. MacMillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR et al. A phase II/III multi-center randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood; prepublished online November 16, 2006; DOI 10.1182/blood-2006-08-013995.

    Google Scholar 

  178. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99:2712–2719.

    PubMed  CAS  Google Scholar 

  179. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:465–471.

    PubMed  CAS  Google Scholar 

  180. Hervé P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75:1017–1023.

    PubMed  Google Scholar 

  181. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 1994; 84:1320–1327.

    PubMed  CAS  Google Scholar 

  182. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95:83–89.

    PubMed  CAS  Google Scholar 

  183. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant. 2001; 28:47–49.

    PubMed  CAS  Google Scholar 

  184. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N.Engl.J.Med. 2001; 345:1098–1104.

    PubMed  CAS  Google Scholar 

  185. Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96:2426–2431.

    PubMed  CAS  Google Scholar 

  186. Besnier DP, Chabannes D, Mahé B, Mussini JM, Baranger TA, Muller JY et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64:49–54.

    PubMed  CAS  Google Scholar 

  187. Dall'Amico R, Rossetti F, Zulian F, Montini G, Murer L, Andreetta B et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br.J.Haematol. 1997; 97:848–854.

    PubMed  Google Scholar 

  188. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359:2078–2083.

    PubMed  Google Scholar 

  189. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J.Exp.Med. 2002; 196:389–399.

    PubMed  CAS  Google Scholar 

  190. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. PNAS 2006; 103:5460–5465.

    PubMed  CAS  Google Scholar 

  191. Li L, Godfrey WR, Porter SB, Ge Y, June CH, Blazar BR et al. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 2005; 106:3068–3073.

    PubMed  CAS  Google Scholar 

  192. Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73:1729–1734.

    PubMed  CAS  Google Scholar 

  193. Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/prednisone v cyclosporine A/prednisone. Transplant. Proc. 1987; 19:2605–2607.

    PubMed  CAS  Google Scholar 

  194. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus meth-ylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin. Transplant. 1987; 1:21–28.

    Google Scholar 

  195. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76:1037–1045.

    PubMed  CAS  Google Scholar 

  196. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N.Engl.J.Med. 1993; 329:1225–1230.

    PubMed  CAS  Google Scholar 

  197. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303–2314.

    PubMed  CAS  Google Scholar 

  198. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol.Blood.Marrow.Transplant. 2000; 6:254–261.

    PubMed  CAS  Google Scholar 

  199. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrex-ate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96:2391–2398.

    PubMed  CAS  Google Scholar 

  200. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am.J.Hematol. 1981; 11:1–8.

    PubMed  CAS  Google Scholar 

  201. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: Randomized study comparing corticosteroids and cyclosporine. Am.J.Med. 1985; 78:978–983.

    PubMed  CAS  Google Scholar 

  202. Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB, Ramsay NK et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56:577–580.

    PubMed  CAS  Google Scholar 

  203. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60:939–942.

    PubMed  CAS  Google Scholar 

  204. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL, Jr. et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104:1559–1564.

    PubMed  CAS  Google Scholar 

  205. Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8:206–212.

    PubMed  CAS  Google Scholar 

  206. Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al Ali HK. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant. 2005; 35:515–519.

    PubMed  CAS  Google Scholar 

  207. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant 2006; 12:37–40.

    PubMed  Google Scholar 

  208. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104:649–654.

    PubMed  CAS  Google Scholar 

  209. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89:1352–1359.

    PubMed  CAS  Google Scholar 

  210. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant. 2005; 35:1003–1010.

    PubMed  CAS  Google Scholar 

  211. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-ver-sus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:1224–1226.

    PubMed  CAS  Google Scholar 

  212. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 30:899–903.

    PubMed  CAS  Google Scholar 

  213. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002; 62:879–889.

    PubMed  CAS  Google Scholar 

  214. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant. 2000; 26:405–411.

    PubMed  CAS  Google Scholar 

  215. Margolis J, Vogelsang G. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. [Review]. Semin.Oncol. 2000; 27:72–77.

    PubMed  CAS  Google Scholar 

  216. Bolanos-Meade J, Jacobsohn D, Anders V, Higman M, Chen A, Phelps M et al. Pentostatin in steroid-refractory chronic graft-versus-host disease. Blood 2005; 106 (Part 1):513a, #1805. Abstract.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Medical University of Graz, Graz, Austria

    Martin Benesch

  2. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA

    H. Joachim Deeg

Authors
  1. Martin Benesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Joachim Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Benesch, M., Deeg, H.J. (2008). Acute Graft-versus-Host Disease. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_25

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation